Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw

Antiresorptive-related osteonecrosis of the jaw (ARONJ) is a rare but serious adverse event of bisphosphonate or denosumab administration; it is associated with severe pain and a deteriorated quality of life. Since its first report in 2003, there have been many studies on its definition, epidemiolog...

Full description

Saved in:
Bibliographic Details
Published inEndocrinology and metabolism (Seoul) Vol. 36; no. 5; pp. 917 - 927
Main Author Ha Young Kim
Format Journal Article
LanguageKorean
Published 대한내분비학회 31.10.2021
Subjects
Denosumab
Diphosphonates
Osteonecrosis
Risk factors
Online AccessGet full text

Cover

More Information
Summary:Antiresorptive-related osteonecrosis of the jaw (ARONJ) is a rare but serious adverse event of bisphosphonate or denosumab administration; it is associated with severe pain and a deteriorated quality of life. Since its first report in 2003, there have been many studies on its definition, epidemiology, pathophysiology, diagnosis, and treatment. Nevertheless, the epidemiology and mechanisms underlying this condition have not yet been fully delineated and several risk factors are known. Moreover, as there is no effective treatment currently available for osteonecrosis of the jaw, prevention is essential. Furthermore, close cooperation between prescribing physicians and dentists is important. The aim of this review was to provide up-to-date information regarding the risk factors and prevention of ARONJ from a physician’s perspective.
Bibliography:The Korean Society of Endocrinology
ISSN:2093-596X